Literature DB >> 6282111

The modification of melphalan toxicity in tumor bearing mice by s-2-(3-aminopropylamino)- ethylphosphorothioic acid (WR 2721).

J L Millar, T J McElwain, R D Clutterbuck, E A Wist.   

Abstract

The toxicity of melphalan in mice was reduced by the injection of S-2-(3-aminopropylamino)-ethylphosphorothioic acid (WR2721). This was seen in terms of reduced toxicity to the stem cells of the bone marrow and intestinal epithelium as well as improved animal survival. Using human melanoma xenografts and growth delay as an end-point, it was demonstrated that WR2721 did not protect this tumor from melphalan. With radio-labelled WR2721, it was shown that WR2721 was rapidly cleared from the blood and actively accumulated by all normal tissues except the CNS. Intact human tumor xenografts and Lewis lung tumors were less able to accumulate WR2721 than normal tissues, but in vitro studies showed that tissue fragments or single cell suspensions of tumors were as efficient as liver fragments or bone marrow cells in accumulating the drug. The rapid clearance of WR2721 and poor vascularity of the intact tumors were thought to be responsible for the differential uptake and protection of normal tissues by WR2721.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6282111     DOI: 10.1097/00000421-198206000-00015

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  13 in total

1.  The effect of pretreatment with thio-TEPA and cytosine arabinoside on megakaryocytopoiesis in rats given a sublethal dose of thio-TEPA.

Authors:  G Tanum; A Sønstevold; A Engeset
Journal:  Blut       Date:  1987-01

Review 2.  Clinical and preclinical modulation of chemotherapy-induced toxicity in patients with cancer.

Authors:  K Hoekman; W J van der Vijgh; J B Vermorken
Journal:  Drugs       Date:  1999-02       Impact factor: 9.546

3.  A phase I trial of irinotecan (CPT-11) with amifostine in patients with metastatic colorectal cancer.

Authors:  Heather Wakelee; George A Fisher
Journal:  Invest New Drugs       Date:  2005-06       Impact factor: 3.850

Review 4.  Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome.

Authors:  C R Culy; C M Spencer
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  Zebrafish as a model system to screen radiation modifiers.

Authors:  Misun Hwang; Cha Yong; Luigi Moretti; Bo Lu
Journal:  Curr Genomics       Date:  2007-09       Impact factor: 2.236

6.  Agents capable of eliminating reactive oxygen species. Catalase, WR-2721, or Cu(II)2(3,5-DIPS)4 decrease experimental colitis.

Authors:  A Keshavarzian; J Haydek; R Zabihi; M Doria; M D'Astice; J R Sorenson
Journal:  Dig Dis Sci       Date:  1992-12       Impact factor: 3.199

7.  Effect of WR-2721 on the toxicity and antitumor activity of the combination of carboplatin and 5-fluorouracil.

Authors:  J A van Laar; C L van der Wilt; M Treskes; W J van der Vijgh; G J Peters
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

8.  Effect of amifostine (Ethyol) on the development of extraembryonic blood vessels in chick embryos.

Authors:  J Höper; A Hanjalic; R Sauer; L Plasswilm
Journal:  Strahlenther Onkol       Date:  1999-01       Impact factor: 3.621

Review 9.  Amifostine: potential for clinically useful cytoprotection.

Authors:  G T Budd; V Lorenzi; R Ganapathi; D Adelstein; R Pelley; T Olencki; D McLain; R M Bukowski
Journal:  Support Care Cancer       Date:  1994-11       Impact factor: 3.603

Review 10.  Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector.

Authors:  C M Spencer; K L Goa
Journal:  Drugs       Date:  1995-12       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.